Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioblastoma 21Brain Neoplasms 15Central Nervous System Neoplasms 14Astrocytoma 9Glioma 7Oligodendroglioma 5Medulloblastoma 4Neoplasms 3Lymphoma 3Gliosarcoma 3Recurrence 2Melanoma 2Lymphoma, AIDS-Related 2Leukemia, Myeloid, Acute 2Uveal Melanoma 1Spinal Cord Neoplasms 1Solid Tumor 1Optic Nerve Glioma 1Newly Diagnosed High Grade Glioma 1Neuroectodermal Tumors 1Lung Neoplasms 1Intraocular Lymphoma 1Familial ependymoma 1Ependymoma 1Drug-Related Side Effects and Adverse Reactions 1Cognition Disorders 1Carcinoma, Non-Small-Cell Lung 1Camurati-Engelmann Syndrome 1Adenocarcinoma, Bronchiolo-Alveolar 1Adenocarcinoma of Lung 1

Interventions

Transcranial Direct Current Stimulation 1Modafinil 1Mental Status and Dementia Tests 1Lomustine 1Exercise 1Donepezil 1DNA Methylation 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Cognition Disorders × Lomustine × Clear all
NCT01290939 2021-02-15

Bevacizumab and Lomustine for Recurrent GBM

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3 Completed
592 enrolled
CNS

Brain Neoplasms, Cognition Disorders, Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡